Emergent Biosolutions
EBS
244 hedge funds and large institutions have $2.35B invested in Emergent Biosolutions in 2019 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 89 increasing their positions, 90 reducing their positions, and 20 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
60% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 20
6% more capital invested
Capital invested by funds: $2.22B → $2.35B (+$135M)
5% more funds holding
Funds holding: 233 → 244 (+11)
1% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 90
2.1% less ownership
Funds ownership: 89.26% → 87.16% (-2.1%)
87% less call options, than puts
Call options by funds: $371K | Put options by funds: $2.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$17.4M |
| 2 |
SAM
Silvercrest Asset Management
New York
|
+$15.2M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$10.2M |
| 4 |
Neuberger Berman Group
New York
|
+$10M |
| 5 |
TCM
Tygh Capital Management
Portland,
Oregon
|
+$9.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$33.3M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$25.1M |
| 3 |
Renaissance Technologies
New York
|
-$17.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.8M |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$9.57M |
EBS Hedge Fund Activity: Q3 2019 in Review
244 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2019, worth a combined $2.35B — up 6.1% from $2.22B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new EBS positions and 20 closed out — a net gain of 12 holders — while 89 added to existing stakes and 90 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $17.4M. The largest seller was State Street, cutting an estimated $33.3M.
- 244 institutional investors held Emergent Biosolutions (EBS) as of Q3 2019, up from 233 in Q2 2019.
- Funds reported $2.35B of Emergent Biosolutions stock for Q3 2019, up 6.1% quarter-over-quarter.
- 32 funds opened new Emergent Biosolutions positions in Q3 2019 and 20 closed out, a net change of +12 holders.
- The largest Emergent Biosolutions buyer in Q3 2019 was Millennium Management, an estimated $17.4M added.
- The largest Emergent Biosolutions seller in Q3 2019 was State Street, an estimated $33.3M sold.
Based on aggregated 13F filings for Q3 2019.